LEO 130852A

Drug Profile

LEO 130852A

Alternative Names: LEO130852A

Latest Information Update: 24 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LEO Pharma
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Skin disorders

Most Recent Events

  • 12 Aug 2015 LEO Pharma completes a phase I trial in Skin disorders in Germany (NCT02392130)
  • 06 Mar 2015 LEO Pharma plans a phase I trial for Skin disorders in Germany (NCT02392130)
  • 01 Mar 2015 Phase-I clinical trials in Skin disorders in Germany (Topical) (NCT02392130)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top